CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been chemically modified to prolong its presence in biological systems. The core sequence is a 30\u2011amino acid peptide containing four substituted residues to improve stability, while the DAC moiety \u2013 typically a maleimidopropionic acid linker \u2013 enables selective, covalent attachment to the single free thiol (Cys\u201134) of serum albumin after reconstitution. This conjugate can serve as a sustained\u2011release reservoir in laboratory investigations. Researchers employ this peptide to explore the mechanisms governing growth hormone (GH) secretion, GHRH receptor activation, and downstream signal transduction cascades. All studies with CJC-1295 DAC are confined to \u4f53\u5916<\/strong> models or non\u2011human animal research; the product is strictly for laboratory use and is not intended for human or veterinary application.<\/p>\n Reproducible experimental outcomes depend on the use of highly characterised material. A CJC-1295 DAC research grade supplier<\/strong> should provide product with purity exceeding 98 %, as determined by orthogonal analytical methods. Minor peptide impurities or truncated sequences can alter receptor binding kinetics or produce off\u2011target signals in cell\u2011based assays. Rigorous testing \u2013 typically reversed\u2011phase high\u2011performance liquid chromatography (RP\u2011HPLC), electrospray ionisation mass spectrometry (ESI\u2011MS), and amino acid analysis \u2013 confirms both identity and quantitative purity. For \u4f53\u5185<\/strong> investigations, endotoxin levels must be stringently controlled (commonly <1 EU\/mg) to avoid confounding immune responses, while the absence of microbial contamination and residual process chemicals is essential. A dependable supplier documents not only the batch\u2011specific purity but also lot\u2011to\u2011lot consistency, enabling long\u2011term studies with comparable results.<\/p>\n Choosing a partner for research\u2011grade CJC-1295 DAC requires evaluation of both technical capability and documentation practices. The supplier should demonstrate proven synthesis expertise, scalable production, and a transparent quality management system. Essential documentation includes a detailed Certificate of Analysis (CoA), a Material Safety Data Sheet (MSDS) compliant with applicable regulations, and stability data under recommended storage conditions. Transparent sourcing of starting materials, adherence to good laboratory practices during manufacturing, and clear communication about in\u2011process controls help ensure that each shipment meets the laboratory\u2019s requirements.<\/p>\n Production of CJC-1295 DAC typically begins with stepwise solid\u2011phase peptide synthesis (SPPS) using Fmoc chemistry. After chain assembly, the peptide is cleaved from the resin and globally deprotected. The reactive maleimide\u2011containing linker is then conjugated to the purified peptide under controlled conditions. Crude product is purified by preparative reversed\u2011phase HPLC, often on a C18 column with a water\u2011acetonitrile gradient containing 0.1 % trifluoroacetic acid. This step removes deletion sequences and process\u2011related impurities. Successful scale\u2011up does not compromise purity; a competent supplier can maintain lot\u2011to\u2011lot uniformity from milligram to gram quantities while providing each batch\u2019s chromatographic trace and mass spectrum.<\/p>\n Comprehensive analytical characterisation is the cornerstone of research\u2011grade material. For CJC-1295 DAC, a typical CoA will include:<\/p>\n A reliable CJC-1295 DAC research grade supplier<\/strong> will provide these data for every batch and, upon request, supply historical lot\u2011comparison summaries to support ongoing investigations that require consistent analyte behaviour.<\/p>\n In the laboratory, CJC-1295 DAC is utilised as a tool to probe the neuroendocrine regulation of GH. Common applications include:<\/p>\n All such studies are carried out with the objective of advancing fundamental knowledge of the GH axis; no conclusions should be extrapolated to human clinical situations.<\/p>\n Research\u2011grade peptides are not intended for direct clinical application, and proper labelling is mandatory. Each vial should explicitly state \u201cFor Research Use Only. Not for Human or Veterinary Use.\u201d The supplier must also assist with accurate customs documentation, including harmonised tariff codes and, where necessary, statements confirming the product is not subject to dual\u2011use export controls. Shipments often travel with cold packs to maintain integrity during transit; lyophilised peptide is generally stable at ambient temperature for a limited period, but refrigerated or frozen delivery minimises thermal stress. Compliance with local and international regulations, such as the European Union\u2019s REACH regulation or the U.S. Toxic Substances Control Act, ensures that the material can be imported without unnecessary delays and that safety data sheets reflect current handling practices.<\/p>\n Obtaining a high\u2011quality research tool begins with selecting a trustworthy CJC-1295 DAC research grade supplier<\/strong>. Prioritise vendors that openly share full analytical characterisation, provide readily accessible safety and handling information, and maintain transparent communication about synthesis and purification workflows. For laboratories planning large\u2011scale or longitudinal studies, it is prudent to discuss bulk pricing, lead times, and the feasibility of reserving a dedicated lot. Building a direct relationship with the supplier\u2019s technical support team can also facilitate troubleshooting of solubility issues or assist with regulatory documentation. By emphasising documented quality and reliable supply, researchers can focus on their experimental questions with confidence in the tools they employ.<\/p>\n \u4ec5\u9650\u7814\u7a76\u7528\u9014\u7684\u8bf4\u660e\uff1a<\/strong> This content is provided for informational purposes only. All products discussed are intended solely for in vitro laboratory research use and are not approved for use in humans, animals, or for any clinical, diagnostic, or therapeutic application.<\/p>","protected":false},"excerpt":{"rendered":" Introduction to CJC-1295 DAC Research Grade Peptide CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been chemically modified to prolong its presence in biological systems. The core sequence is a 30\u2011amino acid peptide containing four substituted residues to improve stability, while the DAC moiety \u2013 typically […]<\/p>\n","protected":false},"author":1,"featured_media":1776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"news_category":[],"class_list":["post-1775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nWhy Research Grade Quality Matters for CJC-1295 DAC<\/h2>\n
Key Criteria for Selecting a CJC-1295 DAC Supplier<\/h2>\n
Synthesis and Purification Methods<\/h3>\n
Quality Control and Analytical Testing<\/h3>\n
\n
Applications of CJC-1295 DAC in Research<\/h2>\n
\n
Ensuring Compliance and Regulatory Standards<\/h2>\n
Frequently Asked Questions about CJC-1295 DAC Research Grade<\/h2>\n
\n
Conclusion and Supplier Selection Tips<\/h2>\n